JAK2V617F阳性骨髓增殖性肿瘤表型异质性的分子分析揭示潜在治疗靶点
该研究对JAK2V617F阳性真性红细胞增多症(PV)和原发性血小板增多症(ET)患者样本进行高通量测序及转录组分析,发现SH2B3突变主要见于PV、SF3B1突变更常见于ET;ET的造血干细胞和巨核-红系祖细胞中炎症信号通路升高,Wnt/β-catenin信号在ET分化中独特上调;抑制Wnt/β-catenin可体外阻断巨核细胞分化,并在JAK2V617F阳性MPN小鼠中降低血小板计数。
要点
- SH2B3突变主要见于PV,SF3B1突变更常见于ET。
- ET的HSC和MEP中炎症信号通路升高,PV中无此现象。
- Wnt/β-catenin信号在ET从HSC向MEP分化中独特上调,抑制后可体外阻断巨核细胞分化。
核心结论
- 研究结果为JAK2V617F阳性PV和ET表型分化的机制提供新见解,并提示Wnt/β-catenin信号是MPN的潜在治疗靶点。
研究设计与样本
- 对JAK2V617F阳性ET和PV患者样本进行高通量测序,并在造血干细胞(HSC)和巨核-红系祖细胞(MEP)水平进行转录组分析。
- 在体外及JAK2V617F阳性MPN小鼠和野生型小鼠中评估Wnt/β-catenin抑制剂对巨核细胞分化和血小板计数的影响。
主要发现
- 鉴定出可能影响表型的两个并发突变:SH2B3突变主要见于PV,SF3B1突变更常见于ET。
- 炎症信号通路在ET的HSC和MEP中升高,而在PV的HSC和MEP中未升高。
- Wnt/β-catenin信号在ET从HSC向MEP的造血分化过程中独特上调,抑制该信号可在体外阻断巨核细胞分化。
- 给予Wnt/β-catenin抑制剂后,JAK2V617F阳性MPN小鼠血小板计数降低,机制为阻断MEP和巨核祖细胞并抑制巨核细胞成熟。
- 在野生型小鼠中,Wnt/β-catenin抑制剂未显著降低血小板计数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JAK2V617F is the most frequent mutation in BCR-ABL-negative myeloproliferative neoplasms (MPNs). It is an important but not the only determinant of MPN phenotype. We performed high-throughput sequencing on JAK2V617F+ essential thrombocythaemia (ET) and polycythaemia vera (PV) patient samples to unveil factors involved in phenotypic heterogeneity and to identify novel therapeutic targets for MPN. Two concurrent mutations that may affect phenotype were identified, including mutations in SH2B3, which is primarily prevalent in PV, and SF3B1, which is more commonly mutated in ET. Next, we conducted transcriptomic analysis at the haematopoietic stem cell (HSC) and megakaryocyte (MK)-erythroid progenitor (MEP) levels. Inflammatory signalling pathways were elevated in both ET HSCs and MEPs, unlike in PV HSCs and MEPs. Notably, Wnt/β-catenin signalling was uniquely upregulated during ET haematopoietic differentiation from HSC to MEP, and inhibiting Wnt/β-catenin signalling blocked MK differentiation in vitro. Consistently, Wnt/β-catenin inhibitor administration decreased platelet counts in JAK2V617F+ MPN mice by blocking MEPs and MK progenitors and by inhibiting maturation of MKs, while in wild-type mice, Wnt/β-catenin inhibitor did not significantly reduce platelet counts. In conclusion, our findings provide new insights into the mechanisms underlying phenotypic differentiation of JAK2V617F+ PV and ET and indicate Wnt/β-catenin signalling as a potential therapeutic target for MPN.
引用
- Gu W, Tong J, Fu R, et al. Molecular analysis of phenotypic heterogeneity in JAK2V617F-positive myeloproliferative neoplasms reveals a potential target for therapy. Br J Haematol. 2023. PMID: 36708268. doi:10.1111/bjh.18669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。